Latest Auditor Review News

Halo Technologies Holdings Ltd reported a $6.06 million half-year loss, narrowing from last year’s $8.04 million, while preparing an $11 million rights issue to bolster its finances amid auditor concerns over asset valuations.

BDO Audit has completed its review of HeraMED Limited’s half-year financial report for June 2025, confirming compliance with accounting standards but highlighting significant uncertainty over the company’s ability to continue as a going concern.

Reckon Limited has delivered a robust half-year performance with a 16% revenue increase and a 29% rise in net profit attributable to members, while declaring a steady fully franked dividend. Despite these gains, the company’s net tangible assets per share remain negative, highlighting ongoing balance sheet pressures.

Waypoint REIT’s half-year update reveals a 3.4% portfolio valuation increase to $2.89 billion, alongside a strategic pause in its $50 million buyback program after $32.9 million in purchases.

Regal Partners estimates at least $35 million in performance fee revenue for the first half of 2025, driven by strong global equity strategies and diverse alternative funds. The full half-year results will be released on 25 August.

Nufarm Finance (NZ) Limited reported a 4.1% increase in net profit after tax to NZD 10.35 million for the half-year ended 31 March 2025, driven by higher interest rates. The company declared an interim distribution of NZD 4.31 per security, payable in October 2024.

MPower Group has completed a pivotal equity conversion of its Narromine Renewable Energy Project, extinguishing $10.36 million in project funding and positioning itself for a $700,000 gain. The company also secured additional financing and advanced its renewable energy pipeline amid ongoing operational challenges.

Big River Industries reported a significant $17 million loss for the half-year ending December 2024, driven by a $20 million non-cash impairment charge and a 3.3% revenue decline. The company also announced a reduced fully franked interim dividend of 2 cents per share.

Mayne Pharma reports a robust first half of FY25 with revenues climbing to $210-$215 million and underlying EBITDA soaring by up to 300%, driven by strong performance in Women's Health.

PEXA Group Limited has updated its half-year guidance, flagging a $15 million non-cash impairment and a significant increase in tax expenses due to deferred tax asset derecognition.